Jiang Yuxia, Ji Lin, Jin Xin, Wu Haiying, He Mingxia, Shen Fenglin, Xu Xiaofeng, Jiang Huifang
Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.
Front Med (Lausanne). 2024 Mar 8;11:1358161. doi: 10.3389/fmed.2024.1358161. eCollection 2024.
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a highly aggressive subtype of T-ALL. No standard chemotherapy regimen exists for patients with recurrent/refractory (R/R) ETP-ALL; in these patients, the primary goal of salvage therapy is to achieve remission as a foundation for consolidation and intensification treatments. This study reports cases of two patients with R/R ETP-ALL who underwent salvage therapy of venetoclax combined with the CAG regimen and achieved complete remission in the bone marrow. Flow cytometry results were negative for minimal residual disease. Both patients were bridged to allogeneic hematopoietic stem cell transplantation (HSCT) and in complete remission over a 3-year follow-up period. These cases show that the use of venetoclax combined with the CAG regimen may offer patients with R/R ETP-ALL an opportunity for allogeneic HSCT.
早期T细胞前体急性淋巴细胞白血病（ETP-ALL）是T-ALL的一种高度侵袭性亚型。对于复发/难治性（R/R）ETP-ALL患者，不存在标准的化疗方案；在这些患者中，挽救治疗的主要目标是实现缓解，作为巩固和强化治疗的基础。本研究报告了2例R/R ETP-ALL患者接受维奈克拉联合CAG方案挽救治疗并在骨髓中实现完全缓解的病例。流式细胞术结果显示微小残留病为阴性。两名患者均接受了异基因造血干细胞移植（HSCT）桥接，并在3年的随访期内处于完全缓解状态。这些病例表明，维奈克拉联合CAG方案的使用可能为R/R ETP-ALL患者提供接受异基因HSCT的机会。
